<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute respiratory distress syndrome: Investigational or ineffective therapies in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute respiratory distress syndrome: Investigational or ineffective therapies in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute respiratory distress syndrome: Investigational or ineffective therapies in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Siegel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Polly E Parsons, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Therapy for patients with acute respiratory distress syndrome (ARDS) is supportive, aimed at improving gas exchange and preventing complications while the underlying condition that precipitated ARDS is addressed. Several potential ARDS-specific pharmacotherapies are being evaluated, although none are recommended as routine therapy because patient-important effects are uncertain [<a href="#rid1">1</a>].</p><p>Investigational and ineffective medical therapies for ARDS are reviewed here. The pathogenesis of ARDS as well as mechanical ventilation strategies and supportive care for ARDS are discussed in separate topics. (See  <a class="medical medical_review" href="/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p class="headingAnchor" id="H1954737418"><span class="h1">CLINICAL TRIALS LINK</span><span class="headingEndMark"> — </span>Numerous trials investigate novel medical therapies and ventilatory interventions for patients with ARDS. These trials have frequent status updates and can be readily accessed at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DARDS%26Search%3DSearch&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNHdDdMmpuuIwvM1ZSQ9ofx%2Fw1tTnrjoTPc93%2B9jxr5ckZQGJg5KM8ogyQyNM0S2FU%3D&amp;TOPIC_ID=1618" target="_blank">US National Institute of Health</a>.</p><p class="headingAnchor" id="H3540992946"><span class="h1">THERAPIES FOR PREVENTION</span><span class="headingEndMark"> — </span>Few trials have rigorously examined strategies to prevent ARDS. <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> has no proven benefit, and trials of inhaled glucocorticoids and beta-2 agonist combinations are awaited.</p><p class="headingAnchor" id="H1042560667"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span>Preclinical and clinical observational studies of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, as an antiplatelet and anti-inflammatory agent, have suggested a potential role for it in the prevention and treatment of ARDS [<a href="#rid2">2-7</a>]. However, in a randomized trial (LIPS-A) of 390 patients at risk of developing ARDS, aspirin was reported to be of no benefit in preventing ARDS [<a href="#rid8">8</a>]. Aspirin was administered at 325 mg followed by 81 mg daily for seven days following presentation to the emergency department and compared with placebo and had no effect on the incidence of ARDS at one week (approximately 10 percent in each group). However, the lower-than-expected rate of ARDS in this study suggested a more modest severity of illness than anticipated, which may have limited the ability to detect a study drug effect.</p><p>Further trials are required before we can consider <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> as a preventive therapy for those at risk for developing ARDS.</p><p>The role of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients with COVID-19-related ARDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Statins and aspirin'</a>.)</p><p class="headingAnchor" id="H3893907664"><span class="h2">Combined inhaled glucocorticoids and beta agonists</span><span class="headingEndMark"> — </span>While human studies of short-acting inhaled and systemic beta-2 agonists have shown no efficacy for the treatment of ARDS, a phase IIa trial of a long-acting inhaled beta-2 agonist (<a class="drug drug_general" data-topicid="8946" href="/d/drug information/8946.html" rel="external">formoterol</a>) combined with an inhaled steroid (<a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>) improved oxygenation compared with placebo [<a href="#rid9">9</a>]. Further trials are needed.</p><p class="headingAnchor" id="H453071072"><span class="h1">THERAPIES FOR TREATMENT</span><span class="headingEndMark"> — </span>Despite preclinical studies that are encouraging, agents that enhance lung repair (eg, granulocyte macrophage colony-stimulating factor, stem cell therapy) and agents that reduce inflammation (eg, systemic glucocorticoids, macrolide antibiotics, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) have no proven benefit and are not routinely administered in patients with ARDS [<a href="#rid1">1</a>].</p><p>Antioxidant supplementation of enteral feeds has proven not beneficial. Most clinicians do not use dietary oil supplementation that contain antioxidants such as omega-3 fatty acids due to a lack of proven benefit and potential harm. This is discussed separately. (See <a class="local">'Ineffective or harmful therapies'</a> below and  <a class="medical medical_review" href="/d/html/1605.html" rel="external">"Nutrition support in intubated critically ill adult patients: Enteral nutrition"</a>.)</p><p>A trial of vitamin D used to treat critically ill patients who were vitamin D-deficient showed no impact on 90-day mortality, post-randomization incidence of ARDS, or other non-fatal outcomes [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H230817685"><span class="h2">Enhancing lung repair</span></p><p class="headingAnchor" id="H3172460"><span class="h3">Granulocyte macrophage colony-stimulating factor</span><span class="headingEndMark"> — </span>Granulocyte macrophage colony-stimulating factor (GM-CSF) has not become a routine therapy for adults with ARDS, because the evidence is still inconclusive.</p><p>GM-CSF plays an important role in repairing injured lung and enhancing alveolar macrophage function [<a href="#rid11">11,12</a>]. Preclinical studies suggest that GM-CSF in the bronchoalveolar lavage fluid of humans with ARDS is associated with better survival [<a href="#rid13">13</a>]. However, human therapeutic trials have shown mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>In one randomized trial of 131 patients with ARDS, compared with placebo, intravenous GM-CSF for 14 days was associated with a nonsignificant reduction in mortality (17 versus 23 percent) and increase in organ failure-free days (15.7 versus 12.8 days) [<a href="#rid14">14</a>]. However, a meta-analysis of pharmacotherapies for patients with ARDS reported no effect of GM-CSF on mortality [<a href="#rid1">1</a>], and another single center randomized trial also showed no difference in mortality, organ failure-, or ventilator-free days [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of inhaled GM-CSF in a small group of patients with pneumonia-associated ARDS demonstrated improvement in oxygenation, lung compliance, and severity of illness scores compared with untreated patients [<a href="#rid15">15</a>]. Further study of inhaled GM-CSF is underway <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3D02595060%26cntry%3D%26state%3D%26city%3D%26dist%3D&amp;token=ZPgO3ZcFSSbcxdUBTN9e3IyQ3TKi9EcIZVFLbS9%2FaeO27rCr6XEuD8WiAkdtDYozBd6uqsC4W1yjVbotTMg2FDUgxAgy33BM%2BfwA6LoJRrIhgQcDTOa%2FQtnMrxdY1LjQ&amp;TOPIC_ID=1618" target="_blank">NCT02595060</a>.</p><p></p><p class="headingAnchor" id="H3505225464"><span class="h3">Stem cells</span><span class="headingEndMark"> — </span>Preclinical studies suggest that treatment with exogenously administered mesenchymal stem cells (MSCs) may help to attenuate lung injury and promote repair [<a href="#rid16">16-18</a>]. In animal models, MSCs appear to secrete growth factors and cytokines capable of modulating local inflammation and promoting tissue repair, improve bacterial clearance, and potentially differentiate into mature cells to replace those that have been injured.</p><p>A phase I randomized trial enrolled 12 patients with ARDS to evaluate the safety and feasibility of using systemically administered allogeneic adipose-derived MSCs [<a href="#rid19">19</a>]. Infusion of MSCs was well tolerated. Compared with placebo, patients treated with MSCs had lower levels of surfactant protein-D on day 5, suggesting amelioration of epithelial cell injury. No significant differences were demonstrated in levels of inflammatory cytokines. The study was not sufficiently powered to assess the impact of treatment on clinically important outcomes, such as survival or duration of mechanical ventilation. A second phase I trial reported similar results [<a href="#rid20">20</a>].</p><p>Several trials are studying the role of mesenchymal or bone marrow-derived human stem cells (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DNCT01775774%26Search%3DSearch&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMVo4pfkVf4L%2FYCz0DtHAke5hrMrubr4PQhPcuH2eRBnQbd6DBtnxOWddoZsyfPn%2B4%3D&amp;TOPIC_ID=1618" target="_blank">NCT01775774</a>; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02804945%3Fterm%3DARDS%26rank%3D48&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNeukpyYQgckmVIn0G6zqurgfjHwFmQ6tbN%2F9V2EHVx6S6LzYwC%2FjoE8cWhxNiydCM%3D&amp;TOPIC_ID=1618" target="_blank">NCT02804945</a>) as a treatment for ARDS.</p><p class="headingAnchor" id="H15"><span class="h2">Anti-inflammatory therapies</span><span class="headingEndMark"> — </span>Mortality is higher among patients with ARDS who have large quantities of neutrophils and proinflammatory cytokines [<a href="#rid21">21,22</a>] and/or low levels of anti-inflammatory cytokines [<a href="#rid23">23</a>]. Based upon these observations, it has been hypothesized that anti-inflammatory medications might improve the outcome of ARDS. However, data have not shown convincing benefit from anti-inflammatory agents including macrolide antibiotics or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. Data favor the administration of glucocorticoids. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H15316065"><span class="h3">Macrolide antibiotics</span><span class="headingEndMark"> — </span>Macrolide antibiotics have both antimicrobial and anti-inflammatory effects. Animal models suggest that these agents may have a beneficial effect in ARDS [<a href="#rid24">24,25</a>].</p><p>To evaluate the effects of macrolide antibiotics in humans with ARDS, an observational study was conducted using data from the Lisofylline and Respiratory Management of Acute Lung Injury (LARMA) trial [<a href="#rid26">26</a>]. Patients with ARDS who received a macrolide antibiotic within the initial 24 hours (n = 47) were compared with patients who did not receive a macrolide antibiotic (n = 188) [<a href="#rid27">27</a>]. There was a trend toward lower 180-day mortality among patients who received a macrolide antibiotic (23 versus 36 percent); after adjusting for potential confounders (eg, patients who received a macrolide antibiotic were less likely to have received low tidal volume ventilation), the lower 180-day mortality became statistically significant (hazard ratio [HR] 0.46, 95% CI 0.23-0.92). Follow-up studies investigating the role of macrolides to treat ARDS have not been performed.</p><p class="headingAnchor" id="H1031451635"><span class="h3">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is a powerful antiplatelet and anti-inflammatory agent that has been studied as a preventative agent in patients with ARDS. However, no trial has been published demonstrating a role for it in the treatment of ARDS, although one trial registered at the  was terminated because of slow recruitment (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3D02326350%26cntry%3D%26state%3D%26city%3D%26dist%3D&amp;token=%2FPYS%2FqsI2OYLx3GGvZwDSDqseij7VsHyintBFpXZ0adDbHaHz18EURKeA%2FTOi%2F1KAdf%2F1phSLPaFr71hmamy9u3lV3lSbHSqu9hq6Zru%2BSK2v12PEafhbZgiA%2BAFmUyM&amp;TOPIC_ID=1618" target="_blank">NCT02326350</a>). (See <a class="local">'Aspirin'</a> above.)</p><p class="headingAnchor" id="H618257580"><span class="h3">Other anti-inflammatory agents</span><span class="headingEndMark"> — </span>Carbon monoxide (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00996840%3Fterm%3DARDS%26rank%3D51&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMxmmr0%2BQHGo05XNGEVi4LUgB6v0kfbc1sIwnzgvtQ5H2P52xeTB%2BUz9zqvw8Faca0%3D&amp;TOPIC_ID=1618" target="_blank">CO</a>) is thought to have anti-inflammatory or antioxidant properties in low doses. Two studies investigating CO are underway, which will examine the role of CO in treating patients with ARDS. One of which is actively recruiting patients (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DNCT03799874%26cntry%3D%26state%3D%26city%3D%26dist%3D&amp;token=U3tTUWPBoW0Aa58IvvYcf%2Flq%2F09IPF2Rwsedu83USY3L%2B4X3CvcYjWpgC%2BIBSZ6DxkAXH4mIfBidU472rGOAq90sRQiWOrJNDYo1b3Y4JmXY70IMCKnzPDeed0gHjZhO&amp;TOPIC_ID=1618" target="_blank">NCT03799874</a>), and one is scheduled to begin enrollment in 2022 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DNCT04870125%26cntry%3D%26state%3D%26city%3D%26dist%3D&amp;token=C9l56KaICM%2BxWSsWb3VtS0mIM7hGYvxECkhQ%2FGJTpJrL%2B4X3CvcYjWpgC%2BIBSZ6DE3jGHVESp4Pv2rYnCQPWcGZ8C5rVnaXRBe2FHbo3tF3QMuGL36oT2%2BYVKQNrToQb&amp;TOPIC_ID=1618" target="_blank">NCT04870125</a>).</p><p class="headingAnchor" id="H3028126188"><span class="h2">Lung transplantation</span><span class="headingEndMark"> — </span>One retrospective series described outcomes in 14 Korean patients with severe ARDS (partial arterial pressure of oxygen:fraction of inspired oxygen ratio &lt;100 mmHg) who were listed for lung transplantation (LTPL) [<a href="#rid28">28</a>]. Most of the patients had inhalation injury from disinfectant and were without end-stage lung disease. Among the 14 listed, nine underwent LTPL as a salvage therapy for ARDS. The number of patients who survived was greater in those who received LTPL compared with those who did not undergo LTPL (89 versus 20 percent); similarly, the median survival was higher in those who underwent LTPL (1996 versus 49 days). A retrospective study evaluating 39 ARDS patients who underwent LTPL showed 87.2 percent 90-day survival, 82.1 percent one-year survival, and 69.2 percent three-year survival, which was similar to results seen in a propensity-matched control group of patients with restrictive lung disease [<a href="#rid29">29</a>]. Further studies are required to examine the effects of LTPL on outcomes and to delineate suitable criteria for LTPL before it can be accepted as an option in patients with severe ARDS.</p><p class="headingAnchor" id="H14351419"><span class="h1">INEFFECTIVE OR HARMFUL THERAPIES</span><span class="headingEndMark"> — </span>A number of potential therapies for ARDS were once regarded as promising but have since proven to be either ineffective or harmful. They include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Antioxidant preparations (<a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, procysteine [L-2-oxothiazolidine-4-carboxylate], <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a>, omega-3 fatty acids, <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, beta carotene, zinc, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> and C, lisofylline) [<a href="#rid26">26,30-34</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous prostaglandin E1 [<a href="#rid35">35,36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil elastase inhibitors [<a href="#rid37">37</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">Ibuprofen</a> [<a href="#rid38">38</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated protein C [<a href="#rid39">39</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> [<a href="#rid40">40-44</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statins [<a href="#rid45">45-48</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surfactant [<a href="#rid49">49-57</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-acting beta-2 agonists (inhaled and systemic) [<a href="#rid58">58-60</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratinocyte growth factor [<a href="#rid61">61</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-beta-1a [<a href="#rid62">62</a>]</p><p></p><p class="headingAnchor" id="H1987048"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17029.html" rel="external">"Patient education: Acute respiratory distress syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy for patients with acute respiratory distress syndrome (ARDS) is supportive, aimed at improving gas exchange and preventing complications while the underlying condition that precipitated ARDS is addressed. Potential ARDS-specific pharmacotherapies are being evaluated, although none are recommended as routine therapy, because patient-important effects are uncertain. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Few trials have rigorously examined strategies to prevent ARDS; thus far, no treatment studied has been shown to be effective. (See <a class="local">'Therapies for prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite preclinical studies that are encouraging, the benefits of agents that enhance lung repair (eg, granulocyte macrophage colony-stimulating factor, stem cell therapy) and agents that reduce inflammation (eg, macrolide antibiotics, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) remain uncertain and require further study before they can be recommended for routine administration in patients with ARDS. (See <a class="local">'Therapies for treatment'</a> above and  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of potential therapies were once regarded as promising in patients with ARDS but have since proven to be either ineffective or harmful. These include various antioxidant preparations (<a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, procysteine, <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a>, omega-3 fatty acids, <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, beta carotene, zinc, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> and C, lisofylline), intravenous prostaglandin E1, neutrophil elastase inhibitors, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, activated protein C, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, statins, surfactant, short-acting beta-2 agonists, keratinocyte growth factor, and interferon-beta-1a. (See <a class="local">'Ineffective or harmful therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Duggal A, Ganapathy A, Ratnapalan M, Adhikari NK. Pharmacological treatments for acute respiratory distress syndrome: systematic review. Minerva Anestesiol 2015; 81:567.</a></li><li><a class="nounderline abstract_t">Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119:3450.</a></li><li><a class="nounderline abstract_t">Boyle AJ, Di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care 2015; 19:109.</a></li><li><a class="nounderline abstract_t">Chen W, Janz DR, Bastarache JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med 2015; 43:801.</a></li><li><a class="nounderline abstract_t">Erlich JM, Talmor DS, Cartin-Ceba R, et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011; 139:289.</a></li><li><a class="nounderline abstract_t">Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39:2393.</a></li><li><a class="nounderline abstract_t">Liang H, Ding X, Li H, et al. Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis. Front Pharmacol 2020; 11:738.</a></li><li><a class="nounderline abstract_t">Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. JAMA 2016; 315:2406.</a></li><li><a class="nounderline abstract_t">Festic E, Carr GE, Cartin-Ceba R, et al. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome. Crit Care Med 2017; 45:798.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, et al. Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. N Engl J Med 2019; 381:2529.</a></li><li><a class="nounderline abstract_t">Paine R 3rd, Wilcoxen SE, Morris SB, et al. Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am J Pathol 2003; 163:2397.</a></li><li><a class="nounderline abstract_t">Baleeiro CE, Christensen PJ, Morris SB, et al. GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1246.</a></li><li><a class="nounderline abstract_t">Matute-Bello G, Liles WC, Radella F 2nd, et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000; 28:1.</a></li><li><a class="nounderline abstract_t">Paine R 3rd, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40:90.</a></li><li><a class="nounderline abstract_t">Herold S, Hoegner K, Vadász I, et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 2014; 189:609.</a></li><li><a class="nounderline abstract_t">Mac Sweeney R, McAuley DF. Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial? Thorax 2012; 67:475.</a></li><li><a class="nounderline abstract_t">McIntyre LA, Moher D, Fergusson DA, et al. Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic Review. PLoS One 2016; 11:e0147170.</a></li><li><a class="nounderline abstract_t">Simonson OE, Mougiakakos D, Heldring N, et al. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Transl Med 2015; 4:1199.</a></li><li><a class="nounderline abstract_t">Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014; 15:39.</a></li><li><a class="nounderline abstract_t">Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015; 3:24.</a></li><li><a class="nounderline abstract_t">Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997; 111:1306.</a></li><li><a class="nounderline abstract_t">Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:113.</a></li><li><a class="nounderline abstract_t">Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125:191.</a></li><li><a class="nounderline abstract_t">Kawashima M, yatsunami J, Fukuno Y, et al. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 2002; 180:73.</a></li><li><a class="nounderline abstract_t">Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 2008; 134:20.</a></li><li><a class="nounderline abstract_t">Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1.</a></li><li><a class="nounderline abstract_t">Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141:1153.</a></li><li><a class="nounderline abstract_t">Chang Y, Lee SO, Shim TS, et al. Lung Transplantation as a Therapeutic Option in Acute Respiratory Distress Syndrome. Transplantation 2018; 102:829.</a></li><li><a class="nounderline abstract_t">Harano T, Ryan JP, Chan EG, et al. Lung transplantation for the treatment of irreversible acute respiratory distress syndrome. Clin Transplant 2021; 35:e14182.</a></li><li><a class="nounderline abstract_t">Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997; 112:164.</a></li><li><a class="nounderline abstract_t">Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20:918.</a></li><li><a class="nounderline abstract_t">Andrews PJ, Avenell A, Noble DW, et al. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. BMJ 2011; 342:d1542.</a></li><li><a class="nounderline abstract_t">Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368:1489.</a></li><li><a class="nounderline abstract_t">Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368:1489.</a></li><li><a class="nounderline abstract_t">Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989; 96:114.</a></li><li><a class="nounderline abstract_t">Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 1999; 27:1478.</a></li><li><a class="nounderline abstract_t">Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004; 32:1695.</a></li><li><a class="nounderline abstract_t">Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.</a></li><li><a class="nounderline abstract_t">Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618.</a></li><li><a class="nounderline abstract_t">Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000; 283:1995.</a></li><li><a class="nounderline abstract_t">Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28:648.</a></li><li><a class="nounderline abstract_t">Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21:1635.</a></li><li><a class="nounderline abstract_t">Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 1999; 14:1.</a></li><li><a class="nounderline abstract_t">Williams JG, Maier RV. Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome). Surgery 1992; 112:270.</a></li><li><a class="nounderline abstract_t">Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173:281.</a></li><li class="breakAll">Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS) http://www.clinicaltrials.gov/ct2/show/NCT01195428 (Accessed on February 08, 2012).</li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370:2191.</a></li><li><a class="nounderline abstract_t">McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014; 371:1695.</a></li><li><a class="nounderline abstract_t">Weg JG, Balk RA, Tharratt RS, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994; 272:1433.</a></li><li><a class="nounderline abstract_t">Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562.</a></li><li><a class="nounderline abstract_t">Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334:1417.</a></li><li><a class="nounderline abstract_t">Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884.</a></li><li><a class="nounderline abstract_t">Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309.</a></li><li><a class="nounderline abstract_t">Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10:R41.</a></li><li><a class="nounderline abstract_t">Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293:470.</a></li><li><a class="nounderline abstract_t">Spragg RG, Taut FJ, Lewis JF, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011; 183:1055.</a></li><li><a class="nounderline abstract_t">Willson DF, Truwit JD, Conaway MR, et al. The Adult Calfactant in Acute Respiratory Distress Syndrome Trial. Chest 2015; 148:356.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, et al. Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184:561.</a></li><li><a class="nounderline abstract_t">Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379:229.</a></li><li><a class="nounderline abstract_t">Perkins GD, Gates S, Park D, et al. The beta agonist lung injury trial prevention. A randomized controlled trial. Am J Respir Crit Care Med 2014; 189:674.</a></li><li><a class="nounderline abstract_t">McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med 2017; 5:484.</a></li><li><a class="nounderline abstract_t">Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 2020; 323:725.</a></li></ol></div><div id="topicVersionRevision">Topic 1618 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937499" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacological treatments for acute respiratory distress syndrome: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19809160" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887566" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559436" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688925" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21725238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32508656" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27179988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240689" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826336" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633611" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891399" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10667491" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926600" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24579839" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504891" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26821255" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26285659" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708472" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529339" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149588" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Infections and the inflammatory response in acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025736" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686976" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182159" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403658" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902249" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116799" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Macrolide antibiotics and survival in patients with acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189633" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lung Transplantation as a Therapeutic Option in Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lung transplantation for the treatment of irreversible acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1617983" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415104" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594003" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594003" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized trial of glutamine and antioxidants in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661155" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470753" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286546" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9070471" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565951" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized clinical trial of activated protein C for the treatment of acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789668" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285017" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ketoconazole prevents acute respiratory failure in critically ill surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222677" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102717" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322565" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254268" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254268" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24835849" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rosuvastatin for sepsis-associated acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268516" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Simvastatin in the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933425" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649125" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618579" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329426" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105072" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bovine surfactant therapy for patients with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542488" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671432" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148720" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855884" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Adult Calfactant in Acute Respiratory Distress Syndrome Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21562125" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomized, placebo-controlled clinical trial of an aerosolizedβ₂-agonist for treatment of acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22166903" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of intravenousβ-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24392848" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The beta agonist lung injury trial prevention. A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28526233" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065831" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of Intravenous Interferonβ-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
